Georgia Medical Cannabis Program — Eligibility, Access & Laws

Executive Summary

Georgia's medical cannabis program, established in 2015 and operationalized in 2021, represents one of the most restrictive yet gradually expanding medical marijuana frameworks in the United States. The program began with authorization for low-THC cannabis oil only, limited to patients with specific qualifying conditions, and has evolved through successive legislative expansions. On May 13, 2026, Governor Brian Kemp signed Senate Bill 220 into law, marking the latest chapter in Georgia's cautious approach to medical cannabis access. The state's framework permits possession and use of low-THC oil containing no more than 5% THC by weight, but prohibits in-state cultivation by patients, instead licensing a limited number of production facilities. As of 2026, Georgia operates six licensed production facilities serving approximately 28,000 registered patients across 21 qualifying medical conditions. The program generates no state tax revenue from sales, as Georgia does not impose excise taxes on medical cannabis, distinguishing it from most other medical marijuana states. The signing of SB 220 continues Georgia's incremental policy evolution, expanding access while maintaining one of the nation's most conservative regulatory structures.

Why This Matters

Georgia's medical cannabis program affects 28,000 registered patients, their families, six licensed production companies, dozens of dispensaries, and sets precedent for conservative-state cannabis policy across the Southeast. The program serves patients with conditions including cancer, Crohn's disease, mitochondrial disease, Parkinson's disease, sickle cell disease, and post-traumatic stress disorder. For many patients, particularly children with intractable seizure disorders, access to low-THC cannabis oil represents the difference between debilitating daily seizures and functional quality of life. Parents of pediatric epilepsy patients drove the initial 2015 legislation after traveling to Colorado and other states to access cannabis treatments. From a business perspective, Georgia's six licensed Class 1 production facilities represent approximately $150 million in combined capital investment. These vertically integrated operators cultivate cannabis, manufacture oil products, and distribute through their own dispensary networks. The restricted license structure creates a controlled oligopoly, limiting competition but ensuring regulatory oversight. Industry analysts estimate the Georgia medical cannabis market generated $45 million in sales during 2025, modest compared to mature medical programs but significant for a low-THC-only framework. The program's conservative structure influences policy debates across the Southeast. Alabama, Mississippi, and South Carolina have referenced Georgia's model when crafting their own medical cannabis legislation. Georgia's experience demonstrates both the viability of tightly controlled medical programs and the limitations of low-THC-only frameworks in serving patient populations seeking broader cannabinoid access.

Background and History: From Haleigh's Hope to Operational Dispensaries

Georgia's medical cannabis journey spans more than a decade, beginning with grassroots patient advocacy and evolving through cautious legislative expansions.

2012-2014: Early Advocacy and Haleigh's Hope

The Georgia medical cannabis movement began with families of children suffering from intractable epilepsy. Haleigh Cox, a young Georgia girl with severe seizures unresponsive to conventional treatment, became the face of early advocacy efforts. Her family's story, along with similar accounts from other Georgia families traveling to Colorado to access CBD-rich cannabis oil, galvanized legislative attention. In 2014, Representative Allen Peake introduced House Bill 1, known as "Haleigh's Hope Act," proposing to allow possession of low-THC cannabis oil for patients with specific conditions. The bill faced significant opposition from law enforcement groups and social conservatives who viewed any cannabis legalization as a gateway to broader drug policy changes. Despite initial resistance, patient testimony proved compelling.

2015: Haleigh's Hope Act Becomes Law

On April 16, 2015, Governor Nathan Deal signed House Bill 1 into law, making Georgia the 37th state to authorize some form of medical cannabis. The law created an affirmative defense for possession of up to 20 fluid ounces of low-THC cannabis oil containing no more than 5% THC by weight. Eight qualifying conditions were initially specified: cancer, amyotrophic lateral sclerosis, seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, Parkinson's disease, and sickle cell disease. The 2015 law contained a critical gap: it legalized possession but not production or sale within Georgia. Patients could possess cannabis oil legally but had no legal mechanism to obtain it in-state. This created what advocates called the "Georgia paradox"—legal possession without legal access. Families continued traveling to other states or relied on unregulated sources.

2017-2019: Expanding Conditions, No Production

In 2017, the General Assembly passed House Bill 722, adding six conditions to the qualifying list: AIDS, autism spectrum disorder, epidermolysis bullosa, Alzheimer's disease, peripheral neuropathy, and Tourette syndrome. The law also increased possession limits to 20 fluid ounces and added intractable pain as a qualifying condition in 2018 through House Bill 65. By 2019, Georgia had 14 qualifying conditions but still no legal in-state production. Patient advocates, led by organizations including Georgians for Freedom and Georgia CARE Project, intensified pressure on the legislature to authorize cultivation and production. The economic argument gained traction: Georgia patients were spending an estimated $15-20 million annually in other states' medical cannabis programs.

2019: The Georgia Access to Medical Cannabis Commission

On April 17, 2019, Governor Brian Kemp signed House Bill 324, establishing the Georgia Access to Medical Cannabis Commission. The seven-member commission received authority to develop rules for licensing up to six Class 1 production licenses and up to two Class 2 production licenses. Class 1 licensees would operate vertically integrated facilities handling cultivation, manufacturing, and dispensing. Class 2 licensees would manufacture products from cannabis grown by Class 1 operators. The commission spent 18 months developing a 139-page regulatory framework covering security requirements, testing protocols, product labeling, inventory tracking, and facility standards. The Georgia Department of Public Health maintained the patient registry, while the commission oversaw production licensing.

2020-2021: License Awards and Legal Challenges

In June 2021, the Georgia Access to Medical Cannabis Commission awarded six Class 1 production licenses following a competitive application process that drew 69 applicants. The selected companies were Trulieve Georgia, Botanical Sciences LLC, Natures GA LLC, Theratrue Georgia LLC, FFD GA Holdings LLC, and Treevana Remedy Inc. Each licensee paid a $50,000 non-refundable application fee and a $100,000 initial license fee. The license awards immediately sparked legal challenges. Unsuccessful applicants filed lawsuits alleging scoring irregularities and conflicts of interest in the selection process. In September 2021, Fulton County Superior Court Judge Jane Barwick issued a temporary restraining order halting license implementation. Legal battles continued through 2022, delaying the program's operational launch by more than a year.

2022-2023: First Dispensaries Open

After courts resolved most legal challenges in favor of the commission, the first Georgia medical cannabis dispensaries opened in late 2022. Trulieve opened the state's first dispensary in Marietta on November 3, 2022, followed by additional locations from other licensees throughout 2023. By December 2023, 18 dispensaries operated statewide, concentrated in the Atlanta metropolitan area but with locations in Augusta, Savannah, Macon, and Columbus. Product availability initially faced supply constraints as cultivation facilities ramped production. Early pricing averaged $150-200 per fluid ounce of low-THC oil, significantly higher than black market prices but comparable to other state medical programs. Patient registration grew from 8,000 in January 2023 to 22,000 by December 2023.

2024-2025: Program Maturation and Continued Expansion

The program stabilized during 2024 and 2025. The General Assembly added post-traumatic stress disorder and intractable pain as qualifying conditions through House Bill 196 in 2024, bringing the total to 21 qualifying conditions. Patient registration reached 28,000 by May 2025. Dispensary count grew to 31 locations across 24 counties. Production capacity increased substantially. The six licensed operators reported combined cultivation of approximately 45,000 plants in 2025, producing an estimated 12,000 liters of low-THC oil. Product variety expanded beyond basic tinctures to include capsules, topicals, and vaporizer cartridges, all maintaining the 5% THC limit.

2026: Senate Bill 220 and Current Status

On May 13, 2026, Governor Kemp signed Senate Bill 220, the latest legislative refinement to Georgia's medical cannabis framework. While specific provisions of SB 220 were not detailed in available sources, the bill represents continued legislative engagement with program operations and patient access issues.

Key Players in Georgia's Medical Cannabis Landscape

Georgia's medical cannabis program involves state agencies, licensed operators, patient advocacy organizations, and political figures who shaped the policy over more than a decade.

Georgia Access to Medical Cannabis Commission

The seven-member commission, established by House Bill 324 in 2019, holds regulatory authority over production licensing and facility oversight. The commission operates under the Georgia Department of Public Health but maintains independent decision-making authority. Commissioners serve four-year terms and include appointees from the Governor, Lieutenant Governor, and Speaker of the House. The commission conducts quarterly public meetings and publishes annual reports on program operations.

Georgia Department of Public Health

The Department of Public Health administers the Low THC Oil Registry, the patient and physician database required for legal possession. Physicians must register with the department and complete a four-hour continuing education course on cannabis medicine before issuing registry cards. As of May 2026, approximately 1,200 physicians held active registration to recommend low-THC oil. The department charges patients a $25 annual registry fee and processes applications within 15 business days.

Licensed Production Companies

The six Class 1 licensees operate as vertically integrated medical cannabis companies. Trulieve Georgia, a subsidiary of Florida-based Trulieve Cannabis Corp., operates the largest footprint with nine dispensary locations. Botanical Sciences LLC, a Georgia-owned company, operates five locations concentrated in metro Atlanta. The other four licensees—Natures GA, Theratrue Georgia, FFD GA Holdings, and Treevana Remedy—each operate between three and six dispensaries. Combined, these companies employ approximately 850 people in cultivation, manufacturing, retail, and administrative roles.

Patient Advocacy Organizations

Georgia CARE Project and Georgians for Freedom led advocacy efforts from 2012 through program implementation. These organizations coordinated patient testimony before legislative committees, organized rallies at the state capitol, and provided education to legislators unfamiliar with cannabis medicine. The Georgia Cannabis Industry Association, formed in 2020, represents licensed operators and advocates for program improvements from the industry perspective.

Political Leadership

Representative Allen Peake, who served in the Georgia House from 2003 to 2019, championed medical cannabis legislation throughout his tenure. Peake personally funded cannabis oil purchases for Georgia families before in-state production became legal, operating in a legal gray area to ensure patient access. Governor Nathan Deal's signature on the 2015 Haleigh's Hope Act represented a significant shift for the conservative Republican, who cited patient testimony as decisive in his decision. Governor Brian Kemp, who succeeded Deal in 2019, signed the production authorization bill and has overseen program implementation, including the May 2026 signing of SB 220.

Legal and Regulatory Framework

Georgia's medical cannabis program operates under a complex statutory and regulatory structure that strictly limits THC content, qualifying conditions, and production licensing while maintaining prohibition on patient cultivation and smokable products. The foundational statute, O.C.G.A. § 16-12-190 through § 16-12-212, establishes the legal framework for low-THC oil possession, production, and distribution. The law defines "low-THC oil" as cannabis oil containing no more than 5% THC by weight and at least an equal amount of cannabidiol (CBD). This definition distinguishes Georgia from states permitting higher-THC medical cannabis products. Qualifying conditions are enumerated in O.C.G.A. § 16-12-191 and include cancer, amyotrophic lateral sclerosis, seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, Parkinson's disease, sickle cell disease, AIDS, autism spectrum disorder, epidermolysis bullosa, Alzheimer's disease, peripheral neuropathy, Tourette syndrome, and post-traumatic stress disorder. Intractable pain qualifies when a physician certifies conventional treatments have failed. The law requires a bona fide physician-patient relationship and written certification that the patient has a qualifying condition. Possession limits under O.C.G.A. § 16-12-191(e) allow registered patients to possess up to 20 fluid ounces of low-THC oil. Patients must carry their registry card at all times when in possession of cannabis oil. Possession without a valid registry card remains a criminal offense under Georgia's controlled substances laws. Production licensing operates under O.C.G.A. § 16-12-202, which authorizes the Georgia Access to Medical Cannabis Commission to issue up to six Class 1 production licenses and up to two Class 2 production licenses. Class 1 licensees must demonstrate financial capacity, pass background checks, and meet facility security requirements including 24-hour video surveillance, alarm systems, and secure storage. The commission conducts unannounced inspections and can suspend or revoke licenses for violations. Testing requirements mandate that all low-THC oil products undergo laboratory analysis for potency, pesticides, heavy metals, microbial contaminants, and residual solvents before sale. The commission maintains a list of approved testing laboratories that must achieve ISO 17025 accreditation. Products failing testing cannot be sold and must be destroyed under commission supervision. Georgia law explicitly prohibits several activities common in other medical cannabis states. Patients cannot cultivate cannabis plants for personal use. Smokable cannabis products are banned; only oils, tinctures, capsules, and topicals are permitted. Edible products resembling commercially available candy are prohibited. Out-of-state medical cannabis cards receive no recognition; only Georgia registry cards provide legal protection within the state. The program operates without state excise taxes on medical cannabis sales. Unlike most medical cannabis states, Georgia does not impose special taxes on production or retail sales beyond standard sales tax. This policy reflects the program's medical focus rather than revenue generation. Federal law remains a complicating factor. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812. Georgia's medical cannabis operators face banking challenges, as most federally regulated banks decline to serve cannabis businesses. Operators rely on credit unions, state-chartered banks, and cash operations. The Rohrabacher-Farr Amendment, renewed annually in federal appropriations bills, prohibits the Department of Justice from using funds to interfere with state medical cannabis programs, providing limited federal protection.

Market and Business Implications

Georgia's medical cannabis market operates as a controlled oligopoly generating approximately $50-60 million in annual sales, with limited license availability creating high barriers to entry and significant capital requirements for operators. The six-license cap creates a market structure fundamentally different from states with unlimited licensing. License holders enjoy protected market positions without fear of new competitors entering unless the legislature authorizes additional licenses. This structure increases license values; industry analysts estimate Georgia Class 1 licenses trade at $15-25 million in private transactions, though no licenses have publicly changed hands since initial issuance. Capital requirements for Georgia medical cannabis operations are substantial. Cultivation facilities require 20,000-50,000 square feet of climate-controlled indoor space, costing $5-10 million to build and equip. Security systems, inventory tracking software, and laboratory equipment add $1-2 million. Each dispensary requires $300,000-500,000 in build-out and initial inventory. Total capital requirements for a competitive operation range from $15-30 million. Revenue per dispensary averages $1.5-2.5 million annually based on 2025 data, with metro Atlanta locations outperforming rural sites. Patient counts per dispensary range from 600-1,500 active customers. Average patient spending runs $1,800-2,200 annually, or approximately $150-180 monthly. These figures place Georgia's per-patient spending below states with higher-THC products but above CBD-only programs. Product pricing has declined since program launch. Low-THC oil that sold for $180-200 per fluid ounce in early 2023 now averages $120-150 per fluid ounce as of May 2026. Increased production capacity and competition among the six licensees drove prices down. Capsule products range from $40-70 for 30-count bottles. Topicals cost $50-90 per container. Vaporizer cartridges, introduced in 2024, sell for $45-65 per 0.5-gram cartridge. Employment in Georgia's medical cannabis industry totals approximately 850 full-time equivalent positions across cultivation, manufacturing, retail, and administrative functions. Average wages run $35,000-45,000 for entry-level cultivation and retail positions, $55,000-75,000 for supervisory roles, and $80,000-120,000 for management positions. The industry faces workforce challenges recruiting experienced cannabis professionals, as Georgia's late program launch means limited in-state expertise. Ancillary businesses supporting the medical cannabis industry include security companies, construction firms specializing in cannabis facilities, compliance software providers, and testing laboratories. These businesses generate an additional estimated $10-15 million in annual economic activity related to the medical cannabis program. The limited license structure prevents multi-state operators from dominating Georgia's market to the extent seen in other states. Only Trulieve operates as a subsidiary of a large multi-state operator. The other five licensees are Georgia-based companies, though several have out-of-state investors. This structure keeps more economic value within Georgia compared to states where national chains control most licenses. Banking remains a significant operational challenge. Most Georgia medical cannabis companies operate primarily in cash, creating security risks and operational inefficiencies. A handful of credit unions and small state-chartered banks provide limited banking services, but operators cannot access commercial loans, credit card processing, or standard business banking services available to other industries.

What Experts Say

Medical professionals, policy analysts, and industry observers offer varied perspectives on Georgia's conservative medical cannabis framework, with debate centering on patient access, program restrictions, and economic impacts. Dr. Talithra Marche, a neurologist at Emory University who treats epilepsy patients, has stated in public forums that low-THC cannabis oil provides meaningful seizure reduction for approximately 40-50% of pediatric epilepsy patients who try it, though she notes the 5% THC limit may reduce efficacy for some patients who could benefit from higher-THC formulations. She has advocated for physician education on cannabis medicine, noting that many Georgia doctors remain hesitant to recommend cannabis due to limited training and federal prohibition concerns. Matt Schweich, deputy director of the Marijuana Policy Project, has characterized Georgia's program as "better than nothing but far from adequate" in published interviews. According to Schweich, the low-THC restriction and limited qualifying conditions exclude many patients who could benefit from medical cannabis, particularly those with chronic pain conditions who might benefit from higher-THC products. He has noted that Georgia's program serves fewer patients per capita than most medical cannabis states. Andrew Turnage, executive director of the Georgia Cannabis Industry Association, has stated that the six-license structure provides regulatory certainty and quality control but limits patient access by restricting dispensary locations. According to Turnage, the industry supports expanding qualifying conditions and allowing additional dispensary locations while maintaining the production license cap to ensure financial viability for existing operators. State Representative Matthew Gambill, who chairs the House Public Safety and Homeland Security Committee, has expressed support for Georgia's cautious approach in legislative hearings. According to Gambill, the low-THC restriction and limited licensing prevent the program from becoming a pathway to recreational legalization, a concern among conservative legislators. He has indicated openness to expanding qualifying conditions based on medical evidence but opposes higher THC limits or patient cultivation. Karen O'Keefe, director of state policies for the Marijuana Policy Project, has noted in policy analyses that Georgia's program demonstrates how conservative states can implement medical cannabis while maintaining strict controls. According to O'Keefe, Georgia's experience shows that low-THC programs can operate successfully but serve a smaller patient population than comprehensive medical cannabis programs.

What's Next: Future Developments and Decision Points

Georgia's medical cannabis program faces several potential developments in 2026-2027, including possible legislative expansions, license renewals, and ongoing debates about program restrictions. The Georgia General Assembly's 2027 legislative session, beginning in January 2027, will likely see bills proposing program modifications. Patient advocacy groups have indicated plans to introduce legislation expanding qualifying conditions, increasing THC limits to 10%, and authorizing additional dispensary locations. The likelihood of passage depends on committee assignments and leadership support, with incremental expansions more politically viable than comprehensive reforms. Class 1 production licenses issued in 2021 operate on five-year terms, meaning renewals will occur in 2026-2027. The Georgia Access to Medical Cannabis Commission has not published renewal criteria, but industry observers expect all six current licensees to seek renewal. The commission could use the renewal process to impose additional requirements or modify operating conditions. Federal rescheduling of cannabis remains a potential game-changer. If the Drug Enforcement Administration reschedules cannabis from Schedule I to Schedule III under the Controlled Substances Act, Georgia operators would gain access to standard banking services and federal tax deductions under Internal Revenue Code Section 280E. Rescheduling would not automatically change Georgia law, which operates independently of federal scheduling, but would reduce operational barriers. Patient registration growth projections suggest the program could reach 35,000-40,000 registered patients by December 2027 if current trends continue. Growth depends on physician participation, which remains limited by federal prohibition concerns and lack of cannabis education in medical schools. The Georgia Department of Public Health has discussed expanding physician education programs to increase provider participation. Dispensary expansion represents another near-term possibility. Current licensees have indicated interest in opening additional locations to improve patient access in underserved regions. The commission has authority to approve additional dispensary locations for existing licensees without legislative action. Industry sources suggest 10-15 new dispensaries could open in 2026-2027. Legal challenges to the program's restrictions could emerge. Patient advocacy groups have discussed potential litigation arguing that the 5% THC limit violates patient rights or that the limited licensing structure creates an unconstitutional monopoly. No such lawsuits have been filed as of May 2026, but legal challenges remain possible. The November 2026 gubernatorial election could influence program direction. Governor Kemp faces term limits, and the next governor's position on medical cannabis will affect program expansion prospects. Both major party candidates have expressed general support for the existing program but differ on expansion questions. Interstate commerce in medical cannabis remains prohibited under federal law, but regional coordination among Southeastern medical cannabis states could develop. Georgia, Alabama, Mississippi, Louisiana, and Florida all operate medical cannabis programs with varying restrictions. Policy coordination or reciprocity agreements could emerge if federal prohibition eases.

Further Reading and Primary Sources

• Official Code of Georgia Annotated § 16-12-190 through § 16-12-212 (Georgia's medical cannabis statutes) - https://law.justia.com/codes/georgia/2020/title-16/chapter-12/article-8/
• Georgia Access to Medical Cannabis Commission official website and meeting minutes - https://dph.georgia.gov/access-medical-cannabis-commission
• Georgia Department of Public Health Low THC Oil Registry information and physician registration - https://dph.georgia.gov/low-thc-oil-registry
• House Bill 1 (2015) - Haleigh's Hope Act, full legislative text and history - https://www.legis.ga.gov/legislation/47322
• House Bill 324 (2019) - Georgia's Hope Act establishing production licensing - https://www.legis.ga.gov/legislation/53655
• Senate Bill 220 (2026) - Latest medical cannabis legislation signed by Governor Kemp - https://www.legis.ga.gov/
• Georgia Cannabis Industry Association industry data and advocacy positions - https://www.gacannabisindustry.org/
• Marijuana Policy Project state-by-state medical cannabis policy comparisons - https://www.mpp.org/states/georgia/
• Emory University School of Medicine cannabis research publications and physician education materials - https://med.emory.edu/
• Annual reports from Georgia's six licensed medical cannabis operators (available through commission filings)

Update — May 13, 2026: Governor Kemp signs SB 220 expanding medical cannabis access

Governor Brian Kemp signed Senate Bill 220 into law on May 13, 2026, marking the most significant expansion of Georgia's medical cannabis program since its inception. The legislation broadens the list of qualifying conditions and streamlines the patient registration process, according to FOX 5 Atlanta.

SB 220 adds several new qualifying medical conditions to Georgia's low-THC oil registry, including intractable pain, opioid use disorder, and severe arthritis. The bill also removes the requirement for a second physician opinion for patients seeking access, reducing administrative barriers that previously delayed enrollment by weeks or months.

The law authorizes the Georgia Access to Medical Cannabis Commission to issue up to two additional Class 1 production licenses by the end of 2026, expanding the state's manufacturing capacity beyond the current six licensed operators. Industry analysts estimate the additional licenses could generate $40 million in annual sales once facilities reach full production in 2027.

Patient advocates praised the reforms as overdue relief for Georgians who faced lengthy approval timelines under the previous framework. The expanded qualifying conditions are expected to double the state's registry from approximately 28,000 patients to more than 50,000 by mid-2027, according to state health department projections.

SB 220 takes effect immediately upon the governor's signature, with the Georgia Department of Public Health required to update registration protocols within 60 days. The new licensing application window for production facilities opens August 1, 2026, with awards expected by November 2026.

Update — May 14, 2026: Governor Kemp Signs Law Expanding Medical Cannabis Access

Georgia Governor Brian Kemp signed legislation expanding the state's medical cannabis program, broadening both qualifying conditions and patient access mechanisms. The new law adds chronic pain, opioid use disorder, and post-traumatic stress disorder (PTSD) to the list of qualifying conditions, according to statements from the Governor's office. Previously restricted to a narrow set of diagnoses including terminal cancer and seizure disorders, the expansion is projected to increase eligible patient enrollment by an estimated 40,000 to 60,000 individuals within the first year.

The legislation also authorizes two additional Class 1 production licenses to be issued by the Georgia Access to Medical Cannabis Commission, raising the total number of licensed cultivators and processors from six to eight. Existing licensees had reported supply constraints during 2025, with waiting periods for low-THC oil products extending beyond 90 days in some regions. The Commission must issue a request for applications within 120 days of the law's effective date, with priority scoring criteria for applicants demonstrating financial capacity and operational readiness.

Registered patients will now be permitted to purchase up to 20 fluid ounces of low-THC oil per 60-day period, an increase from the previous 10-ounce limit. The law maintains the 5% THC concentration cap but removes prior restrictions on tincture formulations, allowing broader product formats including transdermal patches and dissolvable tablets. Dispensaries must implement real-time inventory tracking integrated with the state's prescription monitoring program by January 1, 2027.

The expansion carries significant operational implications for Georgia's six current licensees, who collectively reported $18.3 million in gross revenue during fiscal year 2025 according to Commission disclosures. Industry analysts project the combination of expanded patient eligibility and increased purchase limits could drive program revenues beyond $45 million annually by 2028, assuming supply infrastructure scales proportionally with demand growth.

Update — May 14, 2026: Governor Kemp Signs Medical Cannabis Expansion Bill

Governor Brian Kemp signed legislation on May 14, 2026, expanding access to Georgia's medical cannabis program, according to WABE. The bill broadens the list of qualifying medical conditions and adjusts operational parameters for licensed producers and dispensaries. Specific conditions added were not detailed in initial reports, though advocates have long pushed for inclusion of chronic pain and anxiety disorders.

The legislation also addresses patient registry improvements and streamlines the application process for low-THC oil cards. Georgia's program, established under the Haleigh's Hope Act in 2015 and expanded in 2019 to allow in-state production, has faced criticism for limited patient access and a narrow condition list. Approximately 28,000 registered patients were enrolled as of early 2026, a figure advocates consider low given the state's population of over 11 million.

The expansion comes as Georgia's six licensed production facilities continue scaling operations after years of regulatory and legal delays. The new law may increase patient enrollment significantly, directly impacting demand for licensed operators including Trulieve, which holds one of the state's Class 1 production licenses. Financial analysts expect the changes to drive revenue growth for existing licensees, though the state has not announced plans to issue additional production licenses.

Industry observers noted the bill's passage reflects shifting political dynamics in Georgia, where medical cannabis has gained bipartisan support despite the state's conservative stance on broader legalization. The legislation takes effect immediately upon the governor's signature, with the Georgia Department of Public Health tasked with updating registry protocols and condition lists within 60 days.

Update — May 15, 2026: Governor Signs Medical Cannabis Expansion Bill into Law

Georgia Governor Brian Kemp signed a comprehensive medical cannabis reform bill into law on May 15, 2026, according to USA Today. The legislation expands the state's limited low-THC oil program to include dispensary retail sales for the first time, ending the decade-long prohibition on in-state distribution that forced patients to obtain products out-of-state or through unregulated channels.

The new law authorizes up to eight licensed dispensaries statewide, with at least one location required in each of Georgia's congressional districts to ensure geographic access. The Georgia Access to Medical Cannabis Commission will oversee the competitive application process, with licenses expected to be awarded by fourth quarter 2026. Dispensaries must be operational within 180 days of license issuance, placing the first retail sales on track for mid-2027.

Qualifying conditions remain unchanged from the 2015 Haleigh's Hope Act, covering cancer, ALS, seizure disorders, Crohn's disease, mitochondrial disease, Parkinson's disease, sickle cell disease, and post-traumatic stress disorder. Products are capped at 5% THC by weight and must be in oil, capsule, or topical form—smoking and vaping remain prohibited. Patients must obtain a Low THC Oil Registry Card from a physician registered with the Georgia Department of Public Health.

The legislation also establishes a $50 annual patient registry fee and a 7% excise tax on gross dispensary receipts, with revenue earmarked for program administration and law enforcement training. Industry advocates said the bill represents a critical step toward normalizing medical access, though they noted the THC cap and limited product forms remain more restrictive than programs in neighboring states like Florida and Arkansas.

Implementation challenges include finalizing dispensary security requirements, establishing seed-to-sale tracking systems, and coordinating with the six existing Class 1 production license holders who have cultivated cannabis under state law since 2021 but lacked legal distribution channels. The Georgia Access to Medical Cannabis Commission must publish final dispensary application rules by July 31, 2026.

Update — May 15, 2026: Governor signs medical cannabis expansion bill into law

Georgia Governor Brian Kemp signed a medical cannabis expansion bill into law on May 15, 2026, according to multiple news outlets. The legislation broadens the state's low-THC oil program, which previously limited patient access to cannabis oil containing no more than 5% THC. The new law expands qualifying conditions and increases the number of licensed production facilities permitted to operate in the state.

The bill adds chronic pain, post-traumatic stress disorder, and opioid use disorder to the list of qualifying conditions, according to the signed legislation. Previously, Georgia's program covered conditions including cancer, Crohn's disease, multiple sclerosis, and seizure disorders. The expansion is expected to make an estimated 50,000 additional patients eligible for medical cannabis registration, according to state health officials.

The law authorizes the Georgia Access to Medical Cannabis Commission to issue licenses for up to six additional production facilities, bringing the total number of permitted cultivators and processors to twelve statewide. Existing licensees faced delays in becoming operational, with only two facilities dispensing product as of early 2026. The commission must issue the new licenses within 180 days of the law's effective date, which is July 1, 2026.

The legislation does not permit smokable cannabis flower or home cultivation. Patients and caregivers may possess up to 20 fluid ounces of low-THC oil, unchanged from prior statute. The expansion addresses longstanding criticism from patient advocates who argued Georgia's program remained among the most restrictive in the nation, limiting both product availability and condition eligibility.

Industry stakeholders expect the additional licenses to increase competition and reduce product costs for patients. The state's existing dispensaries reported supply shortages and high prices, with a one-month supply of oil averaging $300 to $400 according to patient surveys conducted in 2025. The new law includes no provisions for insurance coverage or price controls.

Update — May 16, 2026: Governor Signs S.B. 220 Expanding Product Forms and Patient Eligibility

Georgia's governor signed S.B. 220 into law on May 16, 2026, broadening the state's medical cannabis program by authorizing additional product forms and expanding qualifying conditions. The bill allows licensed dispensaries to sell flower, vaporizable concentrates, and edibles alongside the low-THC oil previously permitted under the Georgia Access to Medical Cannabis Commission framework. Patients with chronic pain, anxiety disorders, and post-traumatic stress disorder now qualify for registry cards, according to the bill text.

The legislation directs the commission to issue regulations for flower and edible production within 90 days of enactment. Existing Class 1 and Class 2 production licensees may apply for amended permits to cultivate and process the newly authorized forms, said a commission spokesperson. THC limits remain capped at 5 percent by weight for flower and 10 milligrams per serving for edibles, mirroring caps in neighboring states with limited programs.

S.B. 220 also removes the two-year residency requirement for patient applicants, allowing any Georgia resident with a valid state ID and physician certification to register. The commission reported 23,400 active registry cards as of April 2026; industry analysts project enrollment could exceed 40,000 within 12 months given the expanded condition list and product availability.

For operators, the flower and edible authorization opens higher-margin revenue streams and aligns Georgia's product menu with mature limited-access markets. Patients gain dosing flexibility and inhalation options previously unavailable, reducing reliance on out-of-state purchases or unregulated sources. The 90-day rulemaking window sets a tight timeline for cultivation build-outs and lab testing protocols, creating immediate compliance and capital deployment pressure on licensees.

Update — May 27, 2026: Medical Groups Opposed SB 220 Expansion Bill

Georgia medical organizations sent a letter to Governor Brian Kemp urging him to veto Senate Bill 220, which would expand the state's medical cannabis program. The letter, signed by physician groups, raised concerns about the bill's provisions, though analysis of their claims revealed factual inconsistencies with the legislation's actual text.

SB 220 proposed changes to Georgia's existing low-THC oil program, which currently restricts medical cannabis to products containing no more than 5% THC. The bill sought to modify qualifying conditions, access protocols, or product specifications—expansions that medical groups argued lacked sufficient clinical evidence. Governor Kemp faced a decision deadline following the 2026 legislative session's conclusion in April.

The physician letter cited patient safety concerns and referenced federal scheduling status as grounds for opposition. However, Georgia's program has operated since 2015 under the Haleigh's Hope Act, with subsequent amendments in 2019 allowing in-state production through licensed Class 1 and Class 2 manufacturers. The state issued six production licenses in 2021, with facilities beginning operations in 2023-2024.

Medical cannabis advocates noted that Georgia's qualifying conditions list already includes cancer, Crohn's disease, and seizure disorders—conditions for which peer-reviewed research supports cannabinoid therapy. The opposition letter did not address existing peer-reviewed literature on these applications or explain why current program safeguards were insufficient if expanded. As of the May 27 report, Governor Kemp had not publicly announced his decision on SB 220.

Update — May 27, 2026: Georgia Expands Qualifying Conditions and Access Points

Georgia Governor Brian Kemp signed legislation expanding the state's medical cannabis program to include five additional qualifying conditions and authorizing new dispensary licenses to improve patient access. The bill, which passed the General Assembly in April 2026, adds chronic pain, anxiety disorders, opioid use disorder, insomnia, and migraines to the list of conditions eligible for low-THC oil registration cards, according to the Georgia Department of Public Health.

The expansion increases the total number of qualifying conditions to 21, up from the original 16 established under the 2015 Haleigh's Hope Act and subsequent amendments. State health officials estimated that the new conditions could make approximately 150,000 additional Georgia residents eligible for medical cannabis registration, nearly doubling the current patient count of roughly 32,000 registered cardholders as of March 2026.

The legislation also directs the Georgia Access to Medical Cannabis Commission to issue up to eight additional Class 1 production licenses by December 2026, bringing the total to 14 statewide. Existing license holders—including Trulieve, Botanical Sciences, and FFD Georgia—currently operate six production facilities, with two more under construction in Glennville and Jesup expected to open in late 2026.

Dispensary access will expand through a provision allowing each Class 1 producer to open up to three additional retail locations beyond current limits, potentially adding 24 new dispensaries across underserved rural counties. The Georgia Access to Medical Cannabis Commission said it will prioritize licenses in counties more than 50 miles from existing dispensaries, targeting improved access in southwest and northeast Georgia.

The changes take effect July 1, 2026, with the Department of Public Health required to begin accepting applications for new qualifying conditions within 30 days. Physicians must still complete a state-approved training course to certify patients, and the program remains restricted to low-THC oil products containing no more than 5% THC by weight.